Company Overview and News

0
Cegedim SA : Docavenue, société du Groupe Cegedim, recrute plus de 100 collaborateurs en France pour le déploiement de la télémédecine et de sa solution de vidéo-consultation

2018-07-05 globenewswire
Docavenue, société du Groupe Cegedim, recrute plus de 100 collaborateurs en France pour le déploiement de la télémédecine et de sa solution de vidéo-consultation Boulogne-Billancourt, France, le 5 juillet 2018
CGM

0
Cegedim SA : Avec Docavenue, Cegedim confirme ses ambitions dans la télémédecine

2018-06-29 globenewswire
Cegedim concrétise avec Docavenue, sa plateforme de RDV en ligne, son engagement dans la télémédecine via l'ouverture d'un premier cabinet de téléconsultation en collaboration avec la start-up Healphi, et le lancement prochain d'une solution de télémédecine.
CGM

0
Cegedim SA : Cegedim e-business retenu par SPIE pour la dématérialisation de ses factures

2018-06-07 globenewswire
Boulogne-Billancourt, le 7 juin 2018 Cegedim e-business, acteur majeur de la digitalisation et de l'automatisation des process en Europe, a été choisi par SPIE pour la dématérialisation de ses factures clients en France. Spécialiste des services multi-techniques dans les domaines de l'énergie et des communications, SPIE s'appuie ainsi sur l'expertise de Cegedim e-business pour répondre aux besoins de digitalisation croissants de ses clients.
CGM

0
Cegedim SA : Le MiPih et Cegedim renforcent leur collaboration et unissent leurs compétences pour concevoir et proposer des solutions innovantes à l'ensemble des acteurs de santé

2018-05-25 globenewswire
Le MiPih et Cegedim renforcent leur collaboration et unissent leurs compétences pour concevoir et proposer des solutions innovantes à l'ensemble des acteurs de santé
CGM

0
Cegedim SA : Poursuite de la croissance du chiffre d'affaires

2018-04-26 globenewswire
Cegedim, entreprise innovante de technologies et de services, enregistre au premier trimestre 2018, un chiffre d'affaires consolidé des activités poursuivies de 111,9 millions d'euros, en progression de 1,8% en données publiées et de 2,6% en données organiques par rapport à la même période en 2017.
CGM

0
Cegedim SA: revenue growth continues

2018-04-26 globenewswire
Cegedim, an innovative technology and services company, posted consolidated Q1 2018 revenues from continuing activities of €111.9 million, up 1.8% on a reported basis and 2.6% like for like compared with the same period in 2017.
CGM

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...